Načítá se...
Current State of Immunotherapy for Treatment of Glioblastoma
At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several fail...
Uloženo v:
| Vydáno v: | Curr Treat Options Oncol |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer US
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6394457/ https://ncbi.nlm.nih.gov/pubmed/30790064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-019-0619-4 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|